Early Detection Research Network

Lung

Endostatin, best known as an inhibitor of angiogenesis, has elevated serum levels in several cancers. Overexpression of endostatin and its parent extracellular matrix protein, collagen XVIII have been associated with poor prognosis in NSCLC (non-small cell lung cancer).
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/429/388
Curated
Two
Serum endostatin levels may be useful markers for NSCLC (non-small cell lung cancer). Endostatin is also a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.
a9495de036864d978e1d1db997eaeb6d
no
no
Contents
Lung Reference Set C Application: Rachel Ostroff - SomaLogics (2010)

Analysis of the EDRN lung biomarker samples will enable the next step in development of a clinical diagnostic assay for the differential diagnosis of lung cancer or benign disease in patients with indeterminant pulmonary nodules. The objective is to develop a blood test with sufficient accuracy to identify lung cancer in these patients, which will aid the treating physician in decisions to recommend invasive procedures or watchful waiting.